Journal of Clinical Oncology · 2019 · 12 citations · 0 references
MedicineHematologyOncologyCell TherapyHematologic OncologyImmunotherapyCancer ImmunotherapyHematologic MalignanciesHematopoietic RecoveryImmune ReconstitutionImmune Reconstitution TherapyRelapsed DiseaseAllogeneic Car T-cell TherapyAllogeneic Hematopoietic RecoveryCytopenia RecoveryImmune Reconstitution KineticsImmune-mediated CytopeniasLymphocyte ReconstitutionRelapsed Diffuse Large B-cell LymphomaT Cell Recovery
7545 Background: Cytopenia lasting beyond 30 days has been observed after CAR T cell therapy. Here, we describe the hematopoietic recovery and immune reconstitution following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma. Methods: Patients with available complete blood counts 30 days after axi-cel infusion were eligible for the analysis. Results: Of 31 patients treated on ZUMA-1 (=24) and ZUMA-9 (=7) trials at our institution, grade ≥3 cytopenias were observed in 15 (48%) patients at day 30 (d30), represented by neutropenia in 9 (29%), anemia in 5 (16%), and thrombocytopenia in 13 (42%). Baseline (d-5) characteristics associated with d30 grade ≥3 cytopenia on univariate analysis were ECOG performance status >0 (60% vs 19%, p=0.03) and >3 prior therapies (67% vs 25%, p=0.03). While on study, patients with d30 grade ≥3 cytopenia had a significantly higher need for intravenous immunoglobulins (Ig) (67% vs 25%, p=0.03) and platelet transfusion (73% vs 25%, p=0.01). No significant association was observed between d30 grade ≥3 cytopenia and subsequent grade ≥3 infections (27% vs 31%, p=1), need for growth factor support (both 100%), red blood cell transfusions or diagnosis of myelodysplastic syndromes. At a median follow-up of 2.7 years, a trend for a higher 3-year PFS was observed for patients with d30 grade ≥3 cytopenia (63% vs 35%, p=0.18). Among patients with ongoing response at most recent follow-up, resolution of grade ≥3 cytopenia was observed in 75% of patients at 1 year and 86% at 2 years; recovery in CD4, CD8, CD56, CD19, and IgG was observed in 63%, 100%, 100%, 29%, and 58% of patients at 1 year, and 86%, 100%, 100%, 25% and 50% of patients at 2 years. Among patients with d30 cytopenia, a significant correlation was observed between platelet count and CD56 count (r=+0.64, p<0.001). Conclusions: Grade > 3 cytopenias are common after axi-cel therapy, but resolve in most patients by 1 year. Recovery of CD4 T cells appears to be delayed beyond 1 year in 1/3 of the patients, highlighting the need for prolonged prophylaxis for opportunistic infections.